Semaglutide Injections and Wegovy Therapy in Frankfort, IN

Semaglutide injections with Wegovy are an FDA-approved treatment for chronic weight reduction and long-term weight maintenance in appropriate patients with obesity or overweight.

Wegovy contains semaglutide, a glucagon-like peptide-1 receptor agonist, commonly called a GLP-1 receptor agonist.

Semaglutide can help reduce hunger, increase fullness and lower calorie intake. When combined with nutrition and physical activity, it has produced substantial and sustained weight reduction in large randomized clinical trials.

Current FDA-approved Wegovy options include:

• Standard once-weekly Wegovy injection
• Wegovy HD 7.2 mg once-weekly injection for selected adults who need additional weight reduction
• Once-daily Wegovy tablets for adults

This page focuses primarily on injectable Wegovy therapy.

Wegovy should not be confused with Ozempic or compounded semaglutide. Ozempic contains the same active ingredient but has different FDA-approved indications, while compounded semaglutide is not FDA-approved.

A physician-guided medical weight-loss program can help determine whether Wegovy is appropriate, select the correct dose, monitor side effects and build a long-term strategy for maintaining weight reduction.

To discuss semaglutide and Wegovy therapy in Frankfort, IN, call (765) 259-0545 or contact Charles Turner MD online.

What Is Wegovy?

Wegovy is the FDA-approved brand name for semaglutide used for chronic weight management.

Semaglutide is a long-acting analogue of glucagon-like peptide-1, a naturally occurring hormone released from the gastrointestinal tract after eating.

GLP-1 helps coordinate:

• Appetite
• Satiety
• Glucose-dependent insulin secretion
• Glucagon regulation
• Gastric emptying
• Energy intake

Semaglutide was engineered to resist rapid enzymatic breakdown and remain active long enough for weekly injection.

Is Semaglutide a Peptide?

Yes.

Semaglutide is a peptide-based medication derived from the GLP-1 hormone pathway.

It has been chemically modified to:

• Resist rapid degradation by dipeptidyl peptidase-4
• Bind strongly to albumin
• Remain active for an extended period
• Support once-weekly injection

This is different from many short naturally occurring peptides that are broken down within minutes.

How Does Wegovy Help With Weight Loss?

Wegovy primarily helps patients reduce energy intake.

Semaglutide activates GLP-1 receptors in brain regions involved in:

• Hunger
• Satiety
• Food reward
• Meal termination
• Energy intake

Patients may experience:

• Less hunger between meals
• Earlier fullness while eating
• Longer-lasting satiety
• Reduced food cravings
• Improved control over eating
• Reduced portion size

Wegovy does not directly “melt fat.”

Weight reduction occurs because patients generally consume fewer calories over time while the medication also influences metabolic and glucose-regulatory pathways.

Who Is Wegovy Approved For?

Current FDA labeling indicates Wegovy injection, together with reduced-calorie nutrition and increased physical activity, for long-term weight reduction in:

• Adults with obesity
• Adults with overweight and at least one weight-related comorbid condition
• Pediatric patients age 12 years and older with obesity

The standard adult indication is based on BMI and weight-related medical risk rather than on a specific target number of pounds.

What Weight-Related Conditions Can Matter?

Examples of weight-related comorbid conditions can include:

• High blood pressure
• Abnormal cholesterol
• Type 2 diabetes
• Obstructive sleep apnea
• Cardiovascular disease
• Other obesity-related medical conditions

A physician should evaluate the complete medical picture rather than BMI alone.

Wegovy and Cardiovascular Risk Reduction

Wegovy injection is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults who have:

• Established cardiovascular disease
• Obesity or overweight

The approved cardiovascular outcome includes:

• Cardiovascular death
• Nonfatal heart attack
• Nonfatal stroke

This indication is based on the SELECT cardiovascular-outcomes trial.

What Did the SELECT Trial Show?

SELECT enrolled 17,604 adults with established cardiovascular disease and obesity or overweight who did not have diabetes.

Participants were assigned to semaglutide 2.4 mg or placebo in addition to standard medical care.

A primary major cardiovascular event occurred in:

• 6.5% of participants receiving semaglutide
• 8.0% receiving placebo

This represented an approximately 20% relative reduction in the primary cardiovascular outcome.

These findings are important because they demonstrate that Wegovy's benefits can extend beyond the number on the scale in appropriately selected patients with established cardiovascular disease.

Long-Term Weight Reduction in SELECT

A prespecified SELECT analysis also evaluated body weight over approximately four years.

At week 208, average body-weight change was:

• Approximately 10.2% reduction with semaglutide
• Approximately 1.5% reduction with placebo

Weight reduction was sustained throughout long-term treatment.

The SELECT population differed from the STEP obesity trials because all participants had established cardiovascular disease.

Wegovy and MASH

Wegovy injection also has an FDA-approved indication for selected adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced liver fibrosis.

This indication received accelerated approval based on improvement in liver histology.

Continued approval may depend on confirmation of clinical benefit in ongoing research.

The approved MASH regimen uses the standard 2.4 mg once-weekly Wegovy injection maintenance dose, with 1.7 mg available when 2.4 mg is not tolerated.

Wegovy HD 7.2 mg and Wegovy tablets have not been established for the MASH indication.

What Did the ESSENCE MASH Trial Show?

The Phase 3 ESSENCE trial evaluated adults with biopsy-confirmed MASH and stage 2 or stage 3 liver fibrosis.

At the planned 72-week interim analysis:

• 62.9% of semaglutide-treated participants achieved resolution of steatohepatitis without worsening fibrosis
• 34.3% of placebo-treated participants achieved that outcome
• 36.8% receiving semaglutide had fibrosis improvement without worsening steatohepatitis
• 22.4% receiving placebo had fibrosis improvement without worsening steatohepatitis

Average body-weight reduction was also greater with semaglutide.

MASH requires condition-specific liver evaluation rather than treatment based only on body weight.

How Much Weight Can Patients Lose With Wegovy?

The most widely cited adult obesity evidence comes from STEP 1.

STEP 1 enrolled 1,961 adults with obesity or overweight plus a weight-related condition who did not have diabetes.

All participants received lifestyle intervention.

At 68 weeks, average body-weight change was:

• 14.9% reduction with semaglutide 2.4 mg
• 2.4% reduction with placebo

Among semaglutide-treated participants:

• 86.4% lost at least 5% of body weight
• 69.1% lost at least 10%
• 50.5% lost at least 15%

Individual results vary.

These percentages should not be treated as guaranteed outcomes for every patient.

How Much Weight Can Patients Lose Over Two Years?

STEP 5 followed adults with obesity or overweight for 104 weeks.

Average body-weight change at two years was:

• 15.2% reduction with semaglutide 2.4 mg
• 2.6% reduction with placebo

More than three-quarters of semaglutide-treated participants achieved at least 5% weight reduction.

The study supports Wegovy as a chronic obesity treatment rather than a short-term weight-loss cycle.

What Is Wegovy HD?

Wegovy HD is the FDA-approved 7.2 mg once-weekly semaglutide injection.

FDA approved this higher dose in March 2026 for long-term weight reduction in selected adults.

Current labeling states that an adult may be considered for 7.2 mg when:

• The patient has tolerated Wegovy 2.4 mg once weekly for at least four weeks
• Additional weight reduction is clinically indicated

The maximum adult dose for weight reduction is 7.2 mg once weekly.

Wegovy HD should not be used simply because a patient wants to accelerate weight loss.

How Much Weight Was Lost With Wegovy HD?

The STEP UP Phase 3b trial directly compared:

• Semaglutide 7.2 mg once weekly
• Semaglutide 2.4 mg once weekly
• Placebo

The trial enrolled 1,407 adults with obesity without diabetes.

At 72 weeks, average body-weight reduction was:

• 18.7% with semaglutide 7.2 mg
• 15.6% with semaglutide 2.4 mg
• 3.9% with placebo

The 7.2 mg dose produced statistically greater average weight reduction than 2.4 mg.

Higher-dose treatment also produced more gastrointestinal adverse effects and a substantially higher rate of dysesthesia, or altered skin sensation.

What Is Dysesthesia With Wegovy HD?

Dysesthesia describes abnormal skin sensations such as:

• Tingling
• Burning
• Heightened sensitivity
• Skin discomfort
• Altered sensation

In the current Wegovy label, dysesthesia occurred more often with increasing semaglutide exposure.

In the 7.2 mg clinical program, dysesthesia was reported in approximately:

• 22% receiving Wegovy 7.2 mg
• 6% receiving Wegovy 2.4 mg
• Less than 1% receiving placebo

This side effect should be discussed when deciding whether the potential additional weight reduction from Wegovy HD is worth the higher dose.

Standard Wegovy Injection Dosing

Wegovy injection begins at a low dose and increases gradually.

The standard FDA-approved escalation schedule is:

• Weeks 1 through 4: 0.25 mg once weekly
• Weeks 5 through 8: 0.5 mg once weekly
• Weeks 9 through 12: 1.0 mg once weekly
• Weeks 13 through 16: 1.7 mg once weekly
• Week 17 and thereafter: maintenance dosing based on indication and tolerance

For adult weight reduction, current labeled maintenance options are:

• 1.7 mg once weekly
• 2.4 mg once weekly, which is the recommended maintenance dose

Selected adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction may be considered for 7.2 mg once weekly.

Why Is Wegovy Dose Escalated Slowly?

Gradual escalation reduces the risk of gastrointestinal adverse effects.

Starting immediately at the full maintenance dose can substantially increase:

• Nausea
• Vomiting
• Abdominal discomfort
• Difficulty maintaining hydration

Current FDA labeling allows the clinician to consider delaying dose escalation for four weeks when a patient does not tolerate a dose during escalation.

Patients should not accelerate the schedule independently.

How Is Wegovy Injected?

Wegovy is administered subcutaneously, meaning into the fatty tissue beneath the skin.

Approved injection sites include:

• Abdomen
• Thigh
• Upper arm

The injection is given once weekly on the same day each week.

Wegovy can be administered at any time of day, with or without meals.

Injection sites should be rotated rather than repeatedly using the exact same location.

What If a Wegovy Dose Is Missed?

Current FDA labeling states:

• If the next scheduled dose is more than 48 hours away, administer the missed dose as soon as possible
• If the next scheduled dose is less than 48 hours away, skip the missed dose and resume the regular weekly schedule

If two or more consecutive doses are missed, a lower re-escalation dose may be appropriate to reduce gastrointestinal side effects.

Patients should ask the prescribing clinician how to restart rather than automatically returning to a high maintenance dose.

Can the Injection Day Be Changed?

A patient can generally change the weekly injection day when sufficient time has passed between doses according to prescribing instructions.

The medication should not be injected repeatedly at intervals shorter than directed.

A clinician or pharmacist can provide the exact transition schedule.

Wegovy Pens, Syringes and FlexTouch

Current Wegovy injection is available in several FDA-approved presentation types, which can include:

• Single-dose pens
• Single-dose syringes
• Single-patient-use FlexTouch pens for selected strengths

Patients should receive instructions for the exact device they are prescribed.

A device change may require new administration training.

What Are Wegovy Tablets?

FDA-approved Wegovy tablets provide an oral semaglutide option for adults.

The current dose-escalation schedule is:

• Days 1 through 30: 1.5 mg once daily
• Days 31 through 60: 4 mg once daily
• Days 61 through 90: 9 mg once daily
• Day 91 and thereafter: 25 mg once daily

Wegovy tablets are approved for adult weight reduction and adult cardiovascular-risk reduction in the labeled populations.

They are not currently established for pediatric obesity or the Wegovy MASH indication.

How Effective Are Wegovy Tablets?

The OASIS 4 randomized trial evaluated oral semaglutide 25 mg in adults with obesity or overweight without diabetes.

At week 64, average body-weight change was:

• 13.6% reduction with oral semaglutide 25 mg
• 2.2% reduction with placebo

Participants receiving oral semaglutide were also significantly more likely to achieve 5%, 10%, 15% and 20% weight-reduction thresholds.

Wegovy tablets may be useful for adults who prefer oral therapy, but daily administration has specific fasting instructions and requires consistent adherence.

Can Patients Switch Between Wegovy Injection and Tablets?

Current labeling provides specific switching instructions between the 2.4 mg weekly injection and 25 mg daily tablet.

The transition should be directed by the prescribing clinician.

The milligram numbers are not directly comparable because oral and subcutaneous semaglutide have very different absorption.

Wegovy vs. Ozempic

Wegovy and Ozempic both contain semaglutide.

They are not the same FDA-approved product.

Comparison	Wegovy	Ozempic
Active ingredient	Semaglutide	Semaglutide
Primary weight-management role	FDA-approved for chronic weight reduction in qualifying patients	Not the semaglutide brand specifically approved for chronic weight management
Type 2 diabetes indication	Weight-management product with separate labeled indications	FDA-approved for type 2 diabetes and selected cardiovascular and kidney outcomes
Weight-management maintenance doses	Includes 1.7 mg, recommended 2.4 mg, and selected adult escalation to 7.2 mg	Different labeled dose range

Using the terms “Ozempic therapy” and “Wegovy therapy” interchangeably can create confusion about dosing and FDA-approved indications.

Patients can review semaglutide injections and Ozempic therapy for the diabetes-focused product.

Wegovy vs. Zepbound

Wegovy and Zepbound are both FDA-approved chronic weight-management medications, but they contain different active ingredients.

• Wegovy: semaglutide, a GLP-1 receptor agonist
• Zepbound: tirzepatide, a GIP and GLP-1 receptor agonist

The SURMOUNT-5 head-to-head trial found greater average weight reduction with tirzepatide than semaglutide in adults with obesity without diabetes.

However, treatment choice should also consider:

• Side effects
• Cardiovascular disease
• Sleep apnea
• Previous treatment response
• Insurance coverage
• Long-term access
• Individual preference

Patients can compare options through Wegovy alternatives and Zepbound therapy .

Wegovy vs. Saxenda

Wegovy and Saxenda are both GLP-1 receptor agonists.

• Wegovy contains semaglutide
• Saxenda contains liraglutide

The STEP 8 randomized trial directly compared weekly semaglutide 2.4 mg with daily liraglutide 3.0 mg.

Average weight reduction at 68 weeks was:

• 15.8% with semaglutide
• 6.4% with liraglutide

Patients can review liraglutide injections and Saxenda therapy or Saxenda alternatives .

Wegovy vs. Compounded Semaglutide

FDA-approved Wegovy and compounded semaglutide are not interchangeable regulatory categories.

Wegovy:

• Is FDA-approved
• Has standardized manufacturing
• Has FDA-reviewed dosing and labeling
• Has extensive randomized clinical-trial evidence
• Uses FDA-approved delivery systems

Compounded semaglutide:

• Is not FDA-approved
• Is not an FDA-approved generic Wegovy product
• Does not undergo FDA premarket review for safety, effectiveness or bioequivalence
• May differ in concentration, formulation and delivery system

FDA determined that the national semaglutide injection shortage was resolved in February 2025, substantially narrowing routine shortage-based compounding.

Patient-specific compounding may still be considered only when applicable federal and state requirements are satisfied.

Patients can review compounded semaglutide for weight loss for a detailed explanation.

Why Semaglutide Sodium and Semaglutide Acetate Matter

FDA-approved Wegovy uses semaglutide as its active ingredient.

FDA has warned about compounded products made with salt forms such as:

• Semaglutide sodium
• Semaglutide acetate

These salt forms are chemically different from the active ingredient used in FDA-approved semaglutide medications.

Patients should ask exactly what ingredient is being dispensed when considering any noncommercial preparation.

What Are the Most Common Wegovy Side Effects?

Common adverse reactions include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Abdominal bloating
• Belching
• Gas
• Gastroesophageal reflux symptoms
• Headache
• Fatigue
• Dizziness
• Hair loss

Altered skin sensations, including dysesthesia, are also recognized and are substantially more common with Wegovy HD 7.2 mg.

Patients can review common side effects of GLP-1 medications for a broader discussion.

Why Nausea Is Common During Wegovy Therapy

Semaglutide affects appetite pathways and slows gastric emptying, particularly early in treatment.

Nausea is more likely when:

• The dose is being increased
• Meals are very large
• Meals are high in fat
• A patient eats beyond comfortable fullness
• Hydration is inadequate

Symptoms often improve as the body adapts, but persistent or severe symptoms require medical review.

Nutrition Strategies for Gastrointestinal Tolerance

Depending on the patient's symptoms, practical strategies may include:

• Eating smaller portions
• Eating slowly
• Stopping when comfortably full
• Avoiding very large high-fat meals
• Maintaining adequate fluid intake
• Increasing fiber gradually when appropriate
• Prioritizing protein and nutrient-dense foods

Nutritional counseling can help patients maintain nutritional adequacy while appetite is reduced.

Wegovy and Constipation

Constipation can occur during treatment.

Potential contributing factors include:

• Reduced food intake
• Reduced fluid intake
• Slower gastrointestinal transit
• Lower fiber intake
• Reduced physical activity

Persistent constipation, severe abdominal pain or inability to tolerate food or fluids should be discussed with the prescribing clinician.

Wegovy and Pancreatitis

Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists.

Symptoms can include:

• Severe persistent abdominal pain
• Pain radiating to the back
• Nausea
• Vomiting

Patients with symptoms concerning for pancreatitis require prompt medical evaluation.

Wegovy and Gallbladder Disease

Gallstones and gallbladder inflammation have occurred in Wegovy clinical trials.

Substantial or rapid weight loss can itself increase gallstone risk.

Patients should report:

• Persistent right-upper-abdominal pain
• Fever
• Jaundice
• Vomiting

Wegovy and Kidney Injury

Severe nausea, vomiting or diarrhea can cause dehydration.

Dehydration can contribute to acute kidney injury.

Patients should contact their clinician when gastrointestinal symptoms make it difficult to maintain fluid intake.

Kidney function may require additional monitoring in patients with underlying renal disease or significant volume depletion.

Wegovy and Severe Gastrointestinal Disease

Wegovy can cause severe gastrointestinal adverse reactions.

Current labeling does not recommend Wegovy in patients with severe gastroparesis.

Patients with:

• Persistent vomiting
• Severe prolonged fullness
• Difficulty maintaining nutrition
• Significant gastric-emptying symptoms

need evaluation before continuing treatment.

Wegovy and Diabetic Retinopathy

Patients with type 2 diabetes may require additional eye monitoring.

Rapid improvement in glucose control can temporarily worsen diabetic retinopathy in some patients.

Patients with diabetes should report new or changing vision symptoms during treatment.

Wegovy and Heart Rate

Semaglutide can increase resting heart rate in some patients.

Patients should tell their clinician about:

• Persistent palpitations
• Racing heartbeat at rest
• Unexplained sustained heart-rate increase

Cardiovascular symptoms should be assessed rather than attributed automatically to weight-loss medication.

Wegovy and Anesthesia

Semaglutide delays gastric emptying.

This can create a risk of retained stomach contents during general anesthesia or deep sedation.

Patients should tell clinicians they take Wegovy before:

• Surgery
• Endoscopy
• Procedures requiring anesthesia
• Procedures requiring deep sedation

The procedural team can determine the appropriate medication and fasting plan.

Thyroid C-Cell Tumor Warning

Wegovy carries an FDA boxed warning concerning thyroid C-cell tumors observed in rodents.

It is unknown whether semaglutide causes medullary thyroid carcinoma in humans.

Wegovy is contraindicated in patients with:

• A personal history of medullary thyroid carcinoma
• A family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2

Patients should report a neck mass, persistent hoarseness, difficulty swallowing or unexplained shortness of breath.

Serious Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis and angioedema, have been reported with semaglutide.

Wegovy is contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or the product's excipients.

Wegovy and Pregnancy

Wegovy should not be used for intentional weight reduction during pregnancy.

Current FDA labeling advises discontinuing Wegovy when pregnancy is recognized for weight-reduction or cardiovascular-risk-reduction treatment.

Because semaglutide has a long half-life, patients using Wegovy for weight reduction or cardiovascular-risk reduction should discontinue treatment at least two months before a planned pregnancy.

Pregnancy planning should be discussed before treatment begins.

Can Wegovy Be Used During Breastfeeding?

Breastfeeding recommendations depend on the formulation and the individual clinical situation.

Current labeling specifically advises against breastfeeding during treatment with Wegovy tablets.

Patients using injectable Wegovy should discuss lactation with their clinician based on current prescribing information and the expected benefits and risks.

Can Wegovy Be Used With Ozempic?

No routine combination is recommended.

Wegovy and Ozempic both contain semaglutide.

Using them together can increase semaglutide exposure without established additional benefit.

Can Wegovy Be Used With Zepbound?

Routine combined use is not recommended.

Zepbound contains tirzepatide and also activates the GLP-1 receptor.

Using multiple incretin medications together can increase overlapping adverse effects without established weight-loss benefit.

Can Wegovy Be Used With Saxenda?

Routine combination is not recommended.

Saxenda contains liraglutide, another GLP-1 receptor agonist.

Patients switching between GLP-1 medications should receive a physician-directed transition plan.

How Long Does Wegovy Take to Work?

Some patients notice appetite changes early during dose escalation.

Meaningful weight reduction develops over months.

Because the first 16 weeks are primarily devoted to gradual dose escalation, early weight change should not be compared directly with the final results of 68- or 72-week clinical trials.

How Long Should Wegovy Be Used?

Wegovy is approved for chronic weight management, not as a short-term crash-diet medication.

Clinical trials demonstrate continued benefit during ongoing treatment.

Treatment duration should be individualized according to:

• Weight response
• Medical benefit
• Side effects
• Cardiometabolic health
• Long-term treatment goals
• Access and affordability

What Happens When Wegovy Is Stopped?

Weight regain is common after effective semaglutide therapy is discontinued.

In the STEP 1 extension, participants who stopped semaglutide regained approximately two-thirds of their prior treatment-associated weight loss over the following year on average.

This does not mean every patient must use Wegovy indefinitely.

It does mean that discontinuation should include a maintenance plan.

Why Weight Regain Can Occur

Obesity is a chronic biological condition.

After weight loss, the body can respond with:

• Increased hunger
• Changes in satiety signaling
• Reduced energy expenditure
• Greater biological pressure to regain weight

Stopping a medication that was helping regulate appetite can make these signals more noticeable.

What Should a Wegovy Maintenance Plan Include?

A long-term plan may include:

• Nutrition strategy
• Resistance exercise
• Aerobic activity
• Sleep optimization
• Weight monitoring
• Body-composition monitoring
• Medication continuation or adjustment when appropriate
• Behavioral support

GLP-1 weight-loss coaching can help patients build sustainable habits during active weight loss and maintenance.

Body Composition During Wegovy Therapy

The scale measures total weight but cannot distinguish fat from lean tissue.

Weight reduction with semaglutide generally includes substantial fat loss, but some lean mass can also be lost.

A 2025 prospective DXA study of adults with obesity treated with semaglutide 2.4 mg reported:

• Significant weight reduction
• Substantial reduction in total fat mass
• Initial reduction in lean mass followed by stabilization
• Improvement in handgrip strength over 12 months

This supports monitoring the quality of weight loss rather than focusing only on pounds.

Why Preserve Lean Mass?

Lean tissue contributes to:

• Strength
• Mobility
• Physical function
• Metabolic health
• Healthy aging

Older adults and patients with low baseline muscle mass may be at particular risk for sarcopenia.

Body Composition Tracking With Wegovy

Body composition analysis may evaluate:

• Body-fat percentage
• Lean mass
• Visceral fat
• Total weight

Ongoing body composition tracking can help guide nutrition and exercise changes during treatment.

Protein Intake During Wegovy Therapy

Because appetite can be substantially reduced, some patients unintentionally eat too little protein.

Protein needs vary according to:

• Age
• Body size
• Kidney function
• Physical activity
• Weight-loss rate
• Muscle mass

A clinician or dietitian can help determine an appropriate target.

Resistance Training During Wegovy Therapy

Resistance exercise can support:

• Muscle retention
• Strength
• Physical function
• Bone health
• Weight-maintenance capacity

Personal training for weight loss may help patients build a safe progression based on fitness level and medical history.

Wegovy and Prediabetes

Semaglutide-associated weight reduction can improve glucose regulation.

STEP analyses have reported favorable shifts from prediabetes toward normoglycemia during treatment.

Patients with insulin resistance or prediabetes may benefit from tracking:

• Fasting glucose
• Hemoglobin A1c
• Weight
• Waist circumference
• Other cardiometabolic risk factors

Wegovy and Cholesterol

Weight reduction and semaglutide treatment can improve several cardiometabolic measurements.

Clinical trials have reported favorable changes involving:

• Triglycerides
• Selected cholesterol measurements
• Blood pressure
• Waist circumference
• Glucose regulation

Patients with dyslipidemia should continue appropriate lipid profile monitoring and prescribed cardiovascular treatment.

Wegovy and Blood Pressure

Clinical trials have reported modest average reductions in blood pressure during semaglutide-associated weight loss.

Patients taking antihypertensive medications may need blood-pressure monitoring as weight decreases.

Medication changes should be made by the treating clinician rather than by the patient.

Wegovy and Sleep Apnea

Weight reduction can improve obesity-related obstructive sleep apnea .

However, Wegovy does not currently carry the same specific FDA-approved OSA treatment indication as Zepbound.

Patients should not stop CPAP or another sleep-apnea therapy solely because they are losing weight.

Repeat sleep testing may be appropriate after substantial weight reduction.

Wegovy in Adolescents

Wegovy injection is FDA-approved for chronic weight reduction in pediatric patients age 12 years and older with obesity.

STEP TEENS studied adolescents age 12 to younger than 18 years.

At 68 weeks:

• Mean BMI decreased substantially with semaglutide
• Cardiometabolic risk measurements improved
• More adolescents achieved clinically meaningful weight reduction than with placebo

Wegovy tablets and Wegovy HD 7.2 mg are not established for pediatric weight management.

Can Wegovy Be Used in Children Younger Than 12?

The current approved pediatric weight-management indication begins at age 12 for Wegovy injection.

Younger children require specialist obesity evaluation and age-appropriate treatment.

Clinical research should not be converted into off-label self-treatment protocols.

Who May Not Be a Candidate for Wegovy?

Wegovy is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to semaglutide or Wegovy excipients

Additional caution or individualized review is appropriate for patients with:

• History of pancreatitis
• Gallbladder disease
• Severe gastrointestinal disease
• Severe gastroparesis
• Diabetic retinopathy
• Kidney disease with risk of dehydration
• Pregnancy or pregnancy planning
• Other GLP-1 medications

What Happens at a Wegovy Consultation?

A physician-guided evaluation may include:

• Current weight and BMI
• Waist circumference
• Weight history
• Previous weight-loss attempts
• Current medications
• Blood pressure
• Glucose and hemoglobin A1c
• Lipid profile
• Kidney function
• Liver function
• Gallbladder history
• Pancreatitis history
• Gastrointestinal symptoms
• Cardiovascular disease
• Sleep apnea
• Pregnancy plans
• Nutrition and activity habits

A consultation does not guarantee that Wegovy will be prescribed.

Laboratory Testing Before or During Wegovy Therapy

Not every patient needs the same testing.

Depending on medical history, testing may include:

• Fasting glucose
• Hemoglobin A1c
• Kidney function
• Liver function
• Lipid profile
• Thyroid testing when clinically indicated
• Additional blood testing based on symptoms and medical history

Routine calcitonin screening is not established as an effective strategy for detecting medullary thyroid carcinoma in Wegovy-treated patients.

How Is Progress Monitored?

Useful monitoring can include:

• Body weight
• Waist circumference
• Body-fat percentage
• Lean mass
• Blood pressure
• Appetite
• Food intake
• Gastrointestinal symptoms
• Resting heart rate
• Strength and physical activity
• Blood glucose and A1c when relevant
• Lipid measurements

Monitoring can identify a weight-loss plateau , excessive lean-mass loss or side effects that require a treatment change.

What If Wegovy Is Not Producing Enough Weight Loss?

A physician may first review:

• Current dose
• Time at maintenance dose
• Missed doses
• Calorie intake
• Protein intake
• Physical activity
• Sleep
• Medications associated with weight gain
• Metabolic conditions
• Body composition

For adults tolerating 2.4 mg once weekly for at least four weeks, Wegovy HD 7.2 mg may be considered when additional weight reduction is clinically indicated.

Another medication may also be appropriate.

When Should Another Medication Be Considered?

A switch may be discussed when:

• Side effects remain unacceptable
• Weight response remains inadequate after appropriate treatment
• Insurance or access makes continuation impractical
• A different obesity-related condition favors another medication
• The patient prefers a different route

Patients can compare Wegovy alternatives .

Can Retatrutide Replace Wegovy?

Not currently.

Retatrutide is an investigational triple receptor agonist being studied for obesity.

It is not FDA-approved and cannot currently be used in compounding under federal law.

Patients can review retatrutide therapy for weight loss for current clinical-research information.

What About “Research Semaglutide” Sold Online?

Products labeled only for research use should not be self-injected.

Potential problems include:

• Incorrect identity
• Incorrect concentration
• Peptide impurities
• Microbial contamination
• Endotoxin contamination
• Unknown sterility
• Improper storage

FDA-approved Wegovy should be obtained through legitimate prescription and pharmacy channels.

Can Wegovy Be Combined With Vitamin B12?

Wegovy itself is an FDA-approved semaglutide product and does not require added vitamin B12 for its approved weight-management effect.

Vitamin B12 treatment may be appropriate when a patient has:

• Documented deficiency
• Malabsorption
• Another established indication

Adding B12 to a compounded semaglutide preparation has not been established as producing greater weight loss than FDA-approved Wegovy.

Does Wegovy Cause Hair Loss?

Hair loss is listed among recognized Wegovy adverse reactions.

Hair shedding during substantial weight loss may also be influenced by:

• Rapid calorie reduction
• Low protein intake
• Iron deficiency
• Other nutrient deficiencies
• Physiological stress from rapid weight change

Persistent hair loss may justify review of nutrition and other medical causes.

Does Wegovy Cause “Ozempic Face”?

The term “Ozempic face” is a nonmedical phrase used to describe facial-volume changes after substantial weight loss.

Facial changes can occur after weight loss from many causes, including:

• Medication-assisted weight loss
• Dietary weight loss
• Bariatric surgery

The change is related primarily to loss of facial fat volume rather than a unique toxic effect of semaglutide.

Does Wegovy Cause Muscle Loss?

Some lean mass can be lost during substantial weight reduction.

This is not unique to Wegovy.

The goal is to maximize fat loss while supporting muscle and function through:

• Adequate protein
• Resistance exercise
• Appropriate calorie intake
• Body-composition monitoring

Patients should avoid severe calorie restriction simply because appetite is low.

Does Wegovy Slow Metabolism?

Energy expenditure commonly decreases when body weight falls, regardless of how the weight loss occurs.

This adaptive response is one reason long-term maintenance can be challenging.

Preserving lean mass and maintaining physical activity can support energy expenditure and physical function.

Can Wegovy Help With Cravings?

Clinical studies have reported improvements in eating control and selected food-craving measures during semaglutide treatment.

Individual patients may notice:

• Less persistent hunger
• Less preoccupation with food
• Greater ability to stop eating when full

Medication does not eliminate every behavioral or emotional eating trigger.

Can Wegovy Help With Insulin Resistance?

Weight reduction and GLP-1 receptor activation can improve glucose regulation.

Clinical studies have reported favorable changes in:

• Fasting glucose
• Hemoglobin A1c
• Insulin-related measures
• Prediabetes status

Patients with metabolic syndrome may benefit from monitoring multiple risk factors rather than weight alone.

Does Wegovy Treat Type 2 Diabetes?

Wegovy contains semaglutide and can improve glucose regulation, but Ozempic is the semaglutide brand specifically approved for type 2 diabetes.

Patients with diabetes require a treatment plan that considers:

• A1c goals
• Other diabetes medications
• Risk of hypoglycemia
• Cardiovascular disease
• Kidney disease
• Weight goals

Can Wegovy Be Used With Insulin?

Selected patients with diabetes may use semaglutide alongside insulin under medical supervision.

Because improved glucose control and reduced food intake can increase the risk of hypoglycemia when combined with insulin or certain insulin-secretagogue medications, glucose monitoring and dose adjustment may be needed.

Does Wegovy Work Without Dieting?

Wegovy's approved use includes reduced-calorie nutrition and increased physical activity.

The medication can make calorie reduction easier by reducing hunger and increasing satiety.

A sustainable eating plan remains important for:

• Protein intake
• Fiber
• Micronutrients
• Muscle preservation
• Long-term weight maintenance

Does Wegovy Work Without Exercise?

Weight loss can occur even when exercise is limited, because the medication primarily affects appetite and energy intake.

However, physical activity provides additional benefits involving:

• Cardiovascular fitness
• Muscle preservation
• Bone health
• Insulin sensitivity
• Mobility
• Weight maintenance

Exercise should be adapted to the patient's current health and physical capacity.

Can Wegovy Help After Previous Weight-Loss Attempts?

Yes, many clinical-trial participants had previously tried to lose weight.

Obesity treatment should not require repeated failure with lifestyle measures before medical therapy is considered when a patient meets treatment criteria.

Medication can be integrated with nutrition and physical activity from the beginning.

Frequently Asked Questions About Semaglutide Injections and Wegovy Therapy

What is Wegovy?

Wegovy is an FDA-approved semaglutide medication used for chronic weight management in qualifying adults and adolescents age 12 years and older. Wegovy injection also has cardiovascular and MASH indications in defined adult populations.

Is Wegovy semaglutide?

Yes. Semaglutide is the active ingredient in Wegovy.

Is semaglutide a GLP-1 medication?

Yes. Semaglutide is a GLP-1 receptor agonist.

Is semaglutide a peptide?

Yes. Semaglutide is a modified peptide analogue of human GLP-1 designed for prolonged activity.

How often is Wegovy injected?

Wegovy injection is administered once weekly.

What is the starting Wegovy dose?

The FDA-approved starting dose is 0.25 mg once weekly for the first four weeks.

What is the normal Wegovy maintenance dose?

For adult weight reduction, current labeled maintenance options are 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended for most adults.

What is the highest Wegovy dose?

For adult weight reduction, the current maximum FDA-approved dose is Wegovy HD 7.2 mg once weekly in selected adults who have tolerated 2.4 mg for at least four weeks and need additional weight reduction.

Can everyone take Wegovy HD 7.2 mg?

No. The 7.2 mg dose is an adult weight-reduction option, not the standard starting or maintenance dose for everyone. It is not the labeled maintenance dose for cardiovascular-risk reduction, pediatric obesity or MASH.

How much more weight was lost with Wegovy HD?

In STEP UP, average weight reduction at 72 weeks was 18.7% with 7.2 mg compared with 15.6% with 2.4 mg and 3.9% with placebo.

What is dysesthesia from Wegovy HD?

Dysesthesia is altered or uncomfortable skin sensation such as tingling, burning or increased sensitivity. It occurred more often with 7.2 mg than 2.4 mg in clinical trials.

How much weight can I lose with Wegovy?

In STEP 1, adults receiving semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks compared with 2.4% with placebo. Individual results vary.

How much weight can I lose in pounds?

The number of pounds depends on starting weight. A 15% reduction would equal 30 pounds for someone starting at 200 pounds and 45 pounds for someone starting at 300 pounds, but individual response varies.

How quickly does Wegovy work?

Appetite changes may occur during early dose escalation, while clinically meaningful weight reduction develops over several months.

How long does it take to reach the full Wegovy dose?

The standard escalation reaches the usual adult maintenance phase after approximately 16 weeks when each step is tolerated on schedule.

Can the dose escalation be slowed?

Yes. Current labeling allows clinicians to consider delaying escalation for four weeks when a dose is not tolerated.

What if I miss one Wegovy dose?

If the next dose is more than 48 hours away, the missed dose can generally be taken as soon as possible. If the next dose is less than 48 hours away, skip the missed dose and resume the regular schedule.

What if I miss several Wegovy doses?

After two or more consecutive missed doses, re-escalation from a lower dose may be appropriate to reduce gastrointestinal side effects. Ask the prescriber how to restart.

Where do I inject Wegovy?

Approved subcutaneous injection sites include the abdomen, thigh and upper arm.

Can Wegovy be taken with food?

Injectable Wegovy can be administered with or without food.

Does Wegovy come as a pill?

Yes. FDA-approved Wegovy tablets are available for adults and use a daily dose-escalation schedule to a 25 mg maintenance dose.

Is oral Wegovy as effective as the injection?

Oral Wegovy 25 mg produced substantial weight reduction in the OASIS 4 trial. It should not be assumed identical to injectable dosing because absorption and studied regimens differ.

Can I switch from Wegovy injection to tablets?

Yes, current labeling provides switching instructions between the 2.4 mg weekly injection and 25 mg daily tablets for appropriate adults. The switch should be directed by a prescriber.

Is Wegovy the same as Ozempic?

No. Both contain semaglutide, but they are different FDA-approved products with different indications and dosing.

Is Wegovy better than Ozempic for weight loss?

Wegovy is the semaglutide product specifically studied and approved for chronic weight management at obesity-treatment doses. Ozempic is primarily a type 2 diabetes product.

Is Wegovy the same as compounded semaglutide?

No. Wegovy is FDA-approved. Compounded semaglutide is not FDA-approved and is not an FDA-approved generic Wegovy product.

Can compounded semaglutide produce the same weight loss as Wegovy?

This has not been established for individual compounded formulations. The STEP clinical-trial results apply to standardized semaglutide regimens, not automatically to compounded products.

Is Wegovy better than Zepbound?

Both are highly effective obesity medications. In SURMOUNT-5, tirzepatide produced greater average weight reduction than semaglutide, but Wegovy has additional cardiovascular and MASH indications that may matter for selected patients.

Can Wegovy and Zepbound be used together?

Routine combined use is not recommended because both involve GLP-1 receptor signaling and can produce overlapping adverse effects.

Can Wegovy and Ozempic be used together?

No routine combination is appropriate because both products contain semaglutide.

Can Wegovy and Saxenda be used together?

Routine coadministration is not recommended because both are GLP-1 receptor agonists.

What are the most common Wegovy side effects?

Nausea, diarrhea, vomiting, constipation, abdominal discomfort, headache, fatigue, indigestion, dizziness, bloating, reflux symptoms and hair loss are among the common adverse effects.

Does Wegovy cause nausea?

Yes. Nausea is one of the most common adverse effects and is particularly common during dose escalation.

Does Wegovy cause constipation?

Yes. Constipation is common and can be influenced by reduced food intake, reduced fluid intake and slower gastrointestinal transit.

Does Wegovy cause pancreatitis?

Acute pancreatitis has occurred in patients treated with GLP-1 receptor agonists. Severe persistent abdominal pain requires prompt medical evaluation.

Does Wegovy cause gallstones?

Gallstones and gallbladder inflammation have been reported. Substantial or rapid weight reduction can also increase gallstone risk.

Can Wegovy cause gastroparesis?

Semaglutide delays gastric emptying and can cause significant gastrointestinal symptoms. Wegovy is not recommended in patients with severe gastroparesis.

Does Wegovy affect the kidneys?

Severe vomiting or diarrhea can cause dehydration and acute kidney injury. Patients with persistent gastrointestinal symptoms should maintain communication with their clinician.

Can Wegovy affect my eyes if I have diabetes?

Patients with type 2 diabetes and diabetic retinopathy may need monitoring because rapid glucose improvement can temporarily worsen retinopathy in some patients.

Does Wegovy increase heart rate?

Semaglutide can increase resting heart rate in some patients. Persistent palpitations or a racing heartbeat at rest should be reported.

Does Wegovy reduce heart-attack and stroke risk?

Wegovy injection is FDA-approved to reduce major cardiovascular-event risk in adults with established cardiovascular disease and obesity or overweight based on the SELECT trial.

Does Wegovy treat fatty liver disease?

Wegovy injection is approved for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis. This is a specific liver-disease indication and should not be generalized to every person with fatty liver.

Can Wegovy help sleep apnea?

Weight reduction may improve obesity-related sleep apnea, but Wegovy does not currently carry the specific FDA-approved OSA treatment indication that Zepbound has.

Can teenagers use Wegovy?

Wegovy injection is FDA-approved for chronic weight reduction in adolescents age 12 years and older with obesity.

Can children under 12 use Wegovy?

The current approved pediatric weight-management indication begins at age 12 for Wegovy injection.

Can I take Wegovy while pregnant?

Wegovy should not be used for intentional weight reduction during pregnancy. Current labeling advises discontinuation when pregnancy is recognized for weight-reduction treatment.

How long before pregnancy should Wegovy be stopped?

Current labeling recommends stopping Wegovy at least two months before a planned pregnancy when it is being used for weight reduction or cardiovascular-risk reduction.

Does Wegovy cause hair loss?

Hair loss is a recognized adverse reaction. Rapid weight loss and inadequate protein or micronutrient intake can also contribute to hair shedding.

Does Wegovy cause muscle loss?

Some lean tissue can be lost during substantial weight reduction. Adequate protein, resistance training and body-composition monitoring can help support muscle preservation.

Can I exercise while taking Wegovy?

Yes. Physical activity is part of the approved treatment approach and can support cardiovascular fitness, strength and long-term weight maintenance.

How much protein should I eat on Wegovy?

Protein needs vary by age, body size, kidney function and activity level. A clinician or dietitian can help determine an individualized target.

Can I drink alcohol while taking Wegovy?

Alcohol use should be individualized based on diabetes, pancreatitis risk, liver disease, calorie goals and other medications. Heavy alcohol use can complicate weight management and gastrointestinal tolerance.

Can I stay on Wegovy long term?

Wegovy is intended for chronic weight management in appropriate patients. Long-term continuation depends on benefit, tolerability and medical need.

Will I regain weight if I stop Wegovy?

Weight regain is common after stopping effective semaglutide therapy. A maintenance plan should be discussed before discontinuation.

What if Wegovy stops working?

A physician should review dose, adherence, nutrition, physical activity, sleep, other medications and body composition. Selected adults may be candidates for Wegovy HD or another obesity medication.

What if I cannot tolerate Wegovy?

A slower escalation, lower labeled maintenance dose or different medication may be appropriate depending on the symptoms and medical situation.

What are alternatives to Wegovy?

FDA-approved alternatives include Zepbound, Saxenda or generic liraglutide, Qsymia, Contrave and orlistat. The best choice depends on medical history and treatment goals.

Can retatrutide replace Wegovy?

Not currently. Retatrutide remains investigational and cannot currently be compounded under federal law.

Can I buy semaglutide online without a prescription?

Semaglutide is a prescription medication. Avoid sellers offering injectable products without appropriate prescribing and pharmacy oversight.

Should I use semaglutide labeled for research use?

No. Research-use products are not intended as patient medications and should not be self-injected.

How do I know whether Wegovy is right for me?

A qualified prescriber should evaluate BMI, weight-related conditions, previous treatment, contraindications, medications, pregnancy plans and long-term goals before prescribing.

Explore Semaglutide Injections and Wegovy Therapy in Frankfort, IN

Wegovy is one of the best-studied medications available for chronic obesity treatment.

Its clinical evidence includes substantial weight reduction, long-term maintenance, cardiovascular-risk reduction in selected adults, pediatric obesity treatment and a specific MASH indication.

Current options now include standard weekly injection, Wegovy HD 7.2 mg for selected adults and oral Wegovy tablets for adults.

A physician-guided treatment plan can help determine the appropriate formulation and dose while supporting nutrition, lean-mass preservation, physical activity and long-term maintenance.

Call (765) 259-0545 or contact Charles Turner MD online to request your consultation.

Medical References

• Once-Weekly Semaglutide in Adults With Overweight or Obesity: STEP 1 Randomized Trial
• Continued Semaglutide Treatment Supports Weight-Loss Maintenance: STEP 4 Randomized Trial
• Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: STEP 5 Trial
• Semaglutide Reduces Major Cardiovascular Events in Adults With Cardiovascular Disease and Overweight or Obesity: SELECT
• Long-Term Weight-Loss Effects of Semaglutide in the SELECT Trial
• Once-Weekly Semaglutide in Adolescents With Obesity: STEP TEENS
• Semaglutide 7.2 mg Produces Greater Weight Reduction Than 2.4 mg in Adults With Obesity: STEP UP
• Oral Semaglutide 25 mg Produces Significant Weight Reduction in Adults With Overweight or Obesity: OASIS 4
• Semaglutide Improves Liver Histology in Adults With MASH and Moderate-to-Advanced Fibrosis: ESSENCE
• Once-Weekly Semaglutide Produces Greater Weight Reduction Than Once-Daily Liraglutide: STEP 8
• Semaglutide 2.4 mg Reduces Fat Mass and Supports Muscle Function in Adults With Obesity: SEMALEAN